Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DETECT: Disitamab Vedotin + Tislelizumab in HER2+ mCRC
NCT05578287Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jul 2023
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of disitamab vedotin in colorectal cancer (CRC), sponsored by Sun Yat-sen University. Primary endpoints: Safety at 1 year and Feasibility at 1 year. Started Jul 2023; status: recruiting.
02
Drugs
disitamab vedotin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05578287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05578287.